Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk.Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills show promising effects in the latest clinic trial. Company data suggests the pill is as strong as Ozempic.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.